Molecular Nevogenesis

Overview

Journal Dermatol Res Pract

Publisher Wiley

Specialty Dermatology

Date 2011 Jul 15

PMID 21754924

Citations 22

Authors

Andrew L Ross

Margaret I Sanchez

James M Grichnik

Affiliations

Soon will be listed here.

Abstract

Despite recent advances, the biology underlying nevogenesis remains unclear. Activating mutations in NRAS, HRAS, BRAF, and GNAQ have been identified in benign nevi. Their presence roughly correlates with congenital, Spitz, acquired, and blue nevi, respectively. These mutations are likely to play a critical role in driving nevogenesis. While each mutation is able to activate the MAP kinase pathway, they also interact with a host of different proteins in other pathways. The different melanocytic developmental pathways activated by each mutation cause the cells to migrate, proliferate, and differentiate to different extents within the skin. This causes each mutation to give rise to a characteristic growth pattern. The exact location and differentiation state of the cell of origin for benign moles remains to be discovered. Further research is necessary to fully understand nevus development given that most of the same developmental pathways are also present in melanoma.

Citing Articles

Review: The Key Factors to Melanomagenesis.

Jitian Mihulecea C, Rotaru M Life (Basel). 2023; 13(1).

PMID: 36676131 PMC: 9866207. DOI: 10.3390/life13010181.

New Insights into Melanoma Tumor Syndromes.

Rashid S, Gupta S, McCormick S, Tsao H JID Innov. 2022; 2(6):100152.

PMID: 36387771 PMC: 9641259. DOI: 10.1016/j.xjidi.2022.100152.

The Morpho-Molecular Landscape of Spitz Neoplasms.

Dal Pozzo C, Cappellesso R Int J Mol Sci. 2022; 23(8).

PMID: 35457030 PMC: 9030540. DOI: 10.3390/ijms23084211.

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications.

Vanni I, Tanda E, Dalmasso B, Pastorino L, Andreotti V, Bruno W Front Mol Biosci. 2020; 7:172.

PMID: 32850962 PMC: 7396525. DOI: 10.3389/fmolb.2020.00172.

A six-attribute classification of genetic mosaicism.

Martinez-Glez V, Tenorio J, Nevado J, Gordo G, Rodriguez-Laguna L, Feito M Genet Med. 2020; 22(11):1743-1757.

PMID: 32661356 PMC: 8581815. DOI: 10.1038/s41436-020-0877-3.

References

Thomas N, Edmiston S, Alexander A, Millikan R, Groben P, Hao H . Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev. 2007; 16(5):991-7. DOI: 10.1158/1055-9965.EPI-06-1038. View

Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R . Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One. 2008; 3(7):e2734. PMC: 2444043. DOI: 10.1371/journal.pone.0002734. View

Carr J, Mackie R . Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol. 1994; 131(1):72-7. DOI: 10.1111/j.1365-2133.1994.tb08460.x. View

Pollock P, Harper U, Hansen K, Yudt L, Stark M, Robbins C . High frequency of BRAF mutations in nevi. Nat Genet. 2002; 33(1):19-20. DOI: 10.1038/ng1054. View

Yazdi A, Palmedo G, Flaig M, Puchta U, Reckwerth A, Rutten A . Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol. 2004; 121(5):1160-2. DOI: 10.1046/j.1523-1747.2003.12559.x. View

Takata M, Saida T . Genetic alterations in melanocytic tumors. J Dermatol Sci. 2006; 43(1):1-10. DOI: 10.1016/j.jdermsci.2006.05.002. View

Lamba S, Felicioni L, Buttitta F, Bleeker F, Malatesta S, Corbo V . Mutational profile of GNAQQ209 in human tumors. PLoS One. 2009; 4(8):e6833. PMC: 2730032. DOI: 10.1371/journal.pone.0006833. View

Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle J . High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer. 2004; 111(5):705-10. DOI: 10.1002/ijc.20325. View

Da Forno P, Pringle J, Fletcher A, Bamford M, Su L, Potter L . BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Br J Dermatol. 2009; 161(2):364-72. DOI: 10.1111/j.1365-2133.2009.09181.x. View

10.

Poynter J, Elder J, Fullen D, Nair R, Soengas M, Johnson T . BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 2006; 16(4):267-73. DOI: 10.1097/01.cmr.0000222600.73179.f3. View

11.

Blokx W, van Dijk M, Ruiter D . Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects. Histopathology. 2010; 56(1):121-32. DOI: 10.1111/j.1365-2559.2009.03452.x. View

12.

Papp T, Schipper H, Kumar K, Schiffmann D, Zimmermann R . Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. Melanoma Res. 2005; 15(5):401-7. DOI: 10.1097/00008390-200510000-00008. View

13.

Dong J, Phelps R, Qiao R, Yao S, Benard O, Ronai Z . BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003; 63(14):3883-5. View

14.

Bastian B, Leboit P, Pinkel D . Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000; 157(3):967-72. PMC: 1885704. DOI: 10.1016/S0002-9440(10)64609-3. View

15.

Bloethner S, Snellman E, Lorenzo Bermejo J, Hiripi E, Gast A, Thirumaran R . Differential gene expression in melanocytic nevi with the V600E BRAF mutation. Genes Chromosomes Cancer. 2007; 46(11):1019-27. DOI: 10.1002/gcc.20488. View

16.

Venesio T, Chiorino G, Balsamo A, Zaccagna A, Petti C, Scatolini M . In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol. 2008; 21(6):716-26. DOI: 10.1038/modpathol.2008.41. View

17.

van Dijk M, Bernsen M, Ruiter D . Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol. 2005; 29(9):1145-51. DOI: 10.1097/01.pas.0000157749.18591.9e. View

18.

Uribe P, Andrade L, Gonzalez S . Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol. 2006; 126(1):161-6. DOI: 10.1038/sj.jid.5700011. View

19.

Palmedo G, Hantschke M, Rutten A, Mentzel T, Hugel H, Flaig M . The T1796A mutation of the BRAF gene is absent in Spitz nevi. J Cutan Pathol. 2004; 31(3):266-70. DOI: 10.1111/j.0303-6987.2003.00179.x. View

20.

Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord J . Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol. 2002; 117(6):1483-9. DOI: 10.1046/j.0022-202x.2001.01601.x. View